Skip to main content
Premium Trial:

Request an Annual Quote

Harold Ingalls, Morgan Sheng

Premium
Aruna Biomedical announced this week that it has appointed Harold "Bud" Ingalls to its board of directors.
 
Prior to his current role as CFO of Premier Exhibitions, Ingalls served as vice president and chief financial officer at CardioMEMS. From 2001 to 2006, Ingalls served as vice president of finance and chief financial officer of Serologicals. Prior to Serologicals, Ingalls was employed as president and chief financial officer of LaRoche Industries
 

 
Genentech has appointed Morgan Sheng as vice president of neuroscience, effective Sept. 15, the company said this week. In this newly created position, Sheng will be responsible for directing neurobiology drug discovery efforts at Genentech and will oversee the department of neurobiology.
 

Sheng joins Genentech from the Massachusetts Institute of Technology,where he was Menicon Professor of Neuroscience at the Power Institute for Learning and Memory and RIKEN-MIT Neuroscience Research Center in the departments of brain and cognitive science and biology.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.